Australia sales are basically channel stuffing to try and make the Q3 numbers look less shockingly bad. Why does the distributor need more than a quarters stock on hand?
It should have been obvious from the beginning of 2017 on the basis of the Australian sales growth that it was going to take longer to get surgeon support. The company should have been run lean and scaled only once sales started to take off rather than spending massively and trying to force the market to buy. The lack of buying by the surgeons in the FDA trial should also have been a massive warning to management that things were going to be slower than they hoped. Did they speak to any surgeons before putting together their plans?
I wonder if the board is going to just keep hoping sales will turn around or will they pull the plug early next year?
Australia sales are basically channel stuffing to try and make...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.684M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 29583410 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 59394450 | 39 |
View Market Depth
| Last trade - 16.13pm 20/06/2025 (20 minute delay) ? |
| AXP (ASX) Chart |
Day chart unavailable